Abbreviated new drug application (ANDA)

Absorption, distribution, metabolism, elimination (ADME)

Acinetobacter

Active pharmaceutical ingredient (API)

Adaptive trial

Aerobic bacteria

Ames test

Anaerobic bacteria

Antibiotic, antibacterial and antimicrobial

Antimicrobial resistance (AMR)

Antimicrobial stewardship

Antimicrobial susceptibility testing (AST), resistance testing

Antiseptic

APACHE II score

Bacterial efflux

Bacterial target

Bacterial toxins

Bactericidal

Bacteriophage

Bacteriostatic

Best available therapy (BAT)

Beta (ß)-lactamase

Beta (ß)-lactamase inhibitor (BLI)

Biocide

Biologics license application (BLA)

Bloodstream infection (BSI)

Breakpoint concentration, clinical

Candidate

Carbapenem-resistant Enterobacteriaceae (CRE)

Chemistry, manufacturing and controls (CMC)

Clearance, renal

Clinical Development

Clinical exposure-response (CER) relationship

Clinical study report (CSR)

Cmax

Compassionate use, clinical

Database lock (DBL)

De-escalation

Dosing: BID, TID

Double-blind

Drug product, medicinal product

Efflux-mediated resistance

Eligibility criteria (inclusion/exclusion)

Endpoint, clinical trial

Enterobacterales

Enterobacteriaceae

Enterococcus

Epidemiological cut-off value (ECOFF)

ESKAPE

Eukaryotic cell

Expedited development

Extensively drug-resistant (XDR)

Fastidious bacteria

First-in-human (FIH)

Good clinical practice (GCP)

Good Laboratory Practice (GLP)

Good Manufacturing Practice (GMP)

Gram-positive/negative

High-throughput screen (HTS)

Hit